The Effects of Passive Simulated Jogging on Parameters of Explosive Handgrip in Nondiabetics and Type 2 Diabetics: A Single Arm Study

Table 1

Study subject characteristics.

No.	Gender	Age range	BMI	BL MAX ()	Medications
Nondiabetics
1	M	40-45	42.6	444.2	N/A
2	M	60-65	28.9	386.4	N/A
3	M	30-35	27.5	349.1	N/A
4	F	50-55	31.8	302.0	N/A
5	F	30-35	18.5	224.6	N/A
6	F	25-30	22.9	385.4	N/A
7	M	30-35	20.3	682.5	N/A
8	F	25-30	28.2	278.5	N/A
9	F	40-45	25.41	290.3	Melatonin—10 mg daily
10	F	25-30	29.2	318.7	N/A
11	M	30-35	20.3	682.5	N/A
Mean (SD)	6F, 5M	37 (11.7)	26.9 (6.8)
Diabetics
1	F	70-75	27.8	159.8	Atorvastatin, losartan, synthroid, Jentadueto, clonazepam, brilinta, Famotidine, Wellbutrin, pantoprazole
2	F	50-55	28.8	294.2	Insulin, metformin
3	M	40-45	24.8	368.7	Insulin, levothyroxine, vitamin B12, Truvada, magnesium
4	M	65-70	24	499.2	Insulin, potassium, atorvastatin, metoprolol, lisinopril, amlodipine, pantoprazole, clopidogrel, bumetanide
5	F	55-60	29.3	241.2	Lisinopril, B complex, metformin, insulin
6	F	60-65	44.8	211.8	Tradjenta, metformin
7	F	50-55	29.7	168.7	Metformin
8	F	75-80	29	276.5	Synthroid, Liraglutide
9	M	60-65	29.7	294.2	Metformin
10	F	40-45	26.2	220.6	Glipizide, gemfibrozil, metformin, aspirin
Mean (SD)	7F, 3M	58.9 (10.7)	29.4 (5.5)

This table represents the study participants’ characteristics: study subject number (No.), gender, age (years), calculated Body Mass Index (BMI), baseline maximal peak force (BL MAX), and current medication. Mean and standard deviation (SD) for each column. Age Range is used to protect any participant identifiable information.